Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine

This cohort study examines neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.1) after the second and third doses of the BNT162b2 mRNA vaccine among Danish adults.

Detalles Bibliográficos
Autores principales: Lassaunière, Ria, Polacek, Charlotta, Frische, Anders, Boding, Lasse, Sækmose, Susanne Gjørup, Rasmussen, Morten, Fomsgaard, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107029/
https://www.ncbi.nlm.nih.gov/pubmed/35560054
http://dx.doi.org/10.1001/jamanetworkopen.2022.12073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107029/
https://www.ncbi.nlm.nih.gov/pubmed/35560054
http://dx.doi.org/10.1001/jamanetworkopen.2022.12073

Ejemplares similares